These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25921264)

  • 1. Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.
    Tautz L; Senis YA; Oury C; Rahmouni S
    Bioorg Med Chem; 2015 Jun; 23(12):2786-97. PubMed ID: 25921264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Analysis of Protein Tyrosine Phosphatases in Thrombosis and Hemostasis.
    Rahmouni S; Hego A; Delierneux C; Wéra O; Musumeci L; Tautz L; Oury C
    Methods Mol Biol; 2016; 1447():301-30. PubMed ID: 27514813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis.
    Musumeci L; Kuijpers MJ; Gilio K; Hego A; Théâtre E; Maurissen L; Vandereyken M; Diogo CV; Lecut C; Guilmain W; Bobkova EV; Eble JA; Dahl R; Drion P; Rascon J; Mostofi Y; Yuan H; Sergienko E; Chung TD; Thiry M; Senis Y; Moutschen M; Mustelin T; Lancellotti P; Heemskerk JW; Tautz L; Oury C; Rahmouni S
    Circulation; 2015 Feb; 131(7):656-68. PubMed ID: 25520375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.
    Belcher A; Zulfiker AHM; Li OQ; Yue H; Gupta AS; Li W
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):668-682. PubMed ID: 33297751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein VI - novel target in antiplatelet medication.
    Borst O; Gawaz M
    Pharmacol Ther; 2021 Jan; 217():107630. PubMed ID: 32681846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy.
    Jayakumar T; Hsu CY; Khamrang T; Hsia CH; Hsia CW; Manubolu M; Sheu JR
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29925802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy.
    Tourdot BE; Holinstat M
    Trends Pharmacol Sci; 2017 Nov; 38(11):1006-1015. PubMed ID: 28863985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI.
    Shih TL; Lin KH; Chen RJ; Chen TY; Kao WT; Liu JW; Wang HH; Peng HY; Sun YY; Lu WJ
    J Cell Mol Med; 2021 Oct; 25(19):9434-9446. PubMed ID: 34448532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein-tyrosine phosphatases: a new frontier in platelet signal transduction.
    Senis YA
    J Thromb Haemost; 2013 Oct; 11(10):1800-13. PubMed ID: 24015866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.
    Xiang Q; Pang X; Liu Z; Yang G; Tao W; Pei Q; Cui Y
    Pharmacol Ther; 2019 Nov; 203():107393. PubMed ID: 31356909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases.
    Harbi MH; Smith CW; Nicolson PLR; Watson SP; Thomas MR
    Platelets; 2021 Jan; 32(1):29-41. PubMed ID: 33307909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
    Tullemans BME; Veninga A; Fernandez DI; Aarts MJB; Eble JA; van der Meijden PEJ; Heemskerk JWM; Kuijpers MJE
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Big science for small cells: systems approaches for platelets.
    Holly SP; Parise LV
    Curr Drug Targets; 2011 Nov; 12(12):1859-70. PubMed ID: 21718236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspective on multi-target antiplatelet therapies: high content phenotypic screening as an unbiased source of novel polypharmacological strategies.
    Landré V; Amelio I; Barlev NA; Knight RA; Lisitsa A; Melino G; Antonov AV
    Mini Rev Med Chem; 2015; 15(8):622-9. PubMed ID: 25930110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
    Li W; Gigante A; Perez-Perez MJ; Yue H; Hirano M; McIntyre TM; Silverstein RL
    Circ Res; 2014 Dec; 115(12):997-1006. PubMed ID: 25287063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The progress in the research of antiplatelet agents (1995-2017).
    Benimana O; Zhao L; Kong Y; Li Z; Xie Z
    Future Med Chem; 2017 Jun; 9(10):1087-1110. PubMed ID: 28632424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.